T1	Disorder 16 38	drug induced hepatitis
N1 	Reference T1 UMLS:C1262760	drug induced hepatitis
T2	Pharmacological_substance 46 55	erlotinib
N1000 	Reference T2 MeSH:D000069347	erlotinib
T3	Disorder 73 95	drug induced hepatitis
N2 	Reference T3 UMLS:C1262760	drug induced hepatitis
T7	Disorder 186 200	Hepatotoxicity
N3 	Reference T7 UMLS:C0348754	Hepatotoxicity
N4 	Reference T7 UMLS:C0235378	Hepatotoxicity
T8	Pharmacological_substance 211 220	erlotinib
N1001 	Reference T8 MeSH:D000069347	erlotinib
T13	Disorder 379 388	hepatitis
N5 	Reference T13 UMLS:C0019158	hepatitis
T14	Pharmacological_substance 404 413	erlotinib
N1002 	Reference T14 MeSH:D000069347	erlotinib
T15	Disorder 461 478	pancreatic cancer
N6 	Reference T15 UMLS:C0346647	pancreatic cancer
T16	Disorder 480 494	Hepatotoxicity
N7 	Reference T16 UMLS:C0348754	Hepatotoxicity
N8 	Reference T16 UMLS:C0235378	Hepatotoxicity
T17	Pharmacological_substance 509 518	erlotinib
N1003 	Reference T17 MeSH:D000069347	erlotinib
T18	Disorder 622 631	hepatitis
N9 	Reference T18 UMLS:C0019158	hepatitis
T22	Pharmacological_substance 690 699	gefitinib
N1004 	Reference T22 MeSH:C419708	gefitinib
T23	Pharmacological_substance 703 712	erlotinib
N1005 	Reference T23 MeSH:D000069347	erlotinib
T24	Pharmacological_substance 717 732	EGFR inhibitors
T27	Disorder 784 802	pancreatic cancers
N10 	Reference T27 UMLS:C0346647	pancreatic cancers
T11	Pharmacological_substance 134 184	epidermal growth factor receptor (EGFR) inhibitors
T28	Negation_cue 100 103	not
T30	Disorder 305 331	elevation of transaminases
N11 	Reference T30 UMLS:C0438717	elevation of transaminases
N12 	Reference T30 UMLS:C0438717	elevation of transaminases
T33	Subject 429 438	a patient
T36	Manner_cue 639 643	rare
T37	Disorder 839 861	potential complication
T21	Pharmacological_substance 759 771	chemotherapy
N1006 	Reference T21 MeSH:C403362	chemotherapy
N1007 	Reference T21 MeSH:D004113	chemotherapy
N1008 	Reference T21 MeSH:C057647	chemotherapy
T44	Speculation_cue 815 821	should
